P/E ratio for Esperion Therapeutics (ESPR)
P/E ratio as of April 2025 (TTM): -0.4574
According to Esperion Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.457447. At the end of 2022 the company had a P/E ratio of -1.75.
P/E ratio history for Esperion Therapeutics from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.75 | 235.54% |
| 2021 | -0.5230 | -89.34% |
| 2020 | -4.91 | -70.96% |
| 2019 | -16.9 | 176.89% |
| 2018 | -6.10 | -34.95% |
| 2017 | -9.38 | 149.46% |
| 2016 | -3.76 | -61.83% |
| 2015 | -9.85 | -45.44% |
| 2014 | -18.1 | 128.45% |
| 2013 | -7.90 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | -3.43 | 649.96% | 🇺🇸 USA |
 | 86.7 | -19,044.62% | 🇺🇸 USA |
 | 13.1 | -2,954.78% | 🇺🇸 USA |
 | 16.3 | -3,673.05% | 🇺🇸 USA |
 | -12.5 | 2,632.56% | 🇺🇸 USA |
 | -0.6518 | 42.48% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.